Latest from Xu Hu
Multiple Chinese companies are progressing targeted protein degraders, with oncology the dominant indication and two assets already in Phase III for breast cancer.
Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.
YolTech’s early clinical stage in vivo gene editing therapy YOLT-204 may provide off-the-shelf treatment in transfusion dependent β-thalassemia without conditioning chemotherapy and HSCT.
Plus deals involving Vanda/AnaptysBio, OS Therapies/Ayala, Leveragen/Moonlight Bio, Lantheus/Evergreen, Exicure/GPCR, Arrivent/Lepu, InnoCare/KeyMed/Prolium and more.
Roche's Shanghai-based Accelerator now includes close to 20 Chinese startups across multiple areas including novel modalities and AI-based research, fitting into the Swiss major's strategy of partnering in core areas to access innovation.
China’s State Council has released a wide-ranging set of policy incentives intended to eliminate regulatory barriers and improve market access for innovative drugs.